Lawrence Shulman, MD: The Global Impact of Biosimilar Trastuzumab
Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the global impact of biosimilar trastuzumab.
Transcript:
In your work with the World Health Organization (WHO), have you seen a positive impact of biosimilar availability for patients in countries with limited resources?
In 2015, WHO approved trastuzumab as an essential medicine for cancer. That was the first expensive, patented medicine that they put on their essential medicines list for cancer. Our hope was that that would help to drive the price down, and that’s not in fact happened.
In most of the places that I’m aware of, in sub-Saharan Africa, or areas of the Caribbean or South America, trastuzumab is still not available. It’s still not affordable and we’re not close to making it affordable. I think WHO has played its role in this, companies have picked up the biosimilar torch and have developed their own products, but we still need some effort to bring the price down or find other funding mechanisms that can make drugs like trastuzumab, which can be life-saving, make them affordable to a larger portion of the world’s population.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
